Amcad Biomed (ROCO:4188) GF Value Rank: 3 (As of Sep. 21, 2026) — 25% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4188 Amcad Biomed Corp ROCO:4188
50 GF Score
Price NT$14.00
GF Value NT$9.54
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amcad Biomed GF Value Rank?

Amcad Biomed ROCO:4188 +1.45% 50 GF Value Rank is 3 as of Sep. 21, 2026, which is 25% below its 10-year median of 4.00. GuruFocus rates ROCO:4188 with a GF Score™ of 50/100 and a GF Value™ of NT$9.54 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Amcad Biomed has the GF Value Rank of 3.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Amcad Biomed GF Value Rank Related Terms


ROCO:4188 vs ABT, SYK, MDT: GF Value Rank Comparison

For the Medical Devices subindustry, Amcad Biomed's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amcad Biomed GF Value Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Amcad Biomed's GF Value Rank falls into.


ROCO:4188
50GF Score
Amcad Biomed Corp ROCO:4188
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 3 mean?
Amcad Biomed (ROCO:4188) has a GF Value Rank of 3 as of Sep. 21, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Amcad Biomed and its competitors. This is 25% below median its historical median of 4.00. Over the past decade, Amcad Biomed's GF Value Rank has ranged from 1.00 to 10.00.
Is Amcad Biomed's GF Value Rank too high?
Amcad Biomed's current GF Value Rank of 3 is 25% below median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Amcad Biomed has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amcad Biomed's GF Value Rank compare to ABT and SYK?
Amcad Biomed's GF Value Rank of 3 can be compared against companies in the Medical Devices & Instruments industry. Historically, Amcad Biomed's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Devices & Instruments company?
A good GF Value Rank depends on the Medical Devices & Instruments industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Amcad Biomed and its competitors. Amcad Biomed's current GF Value Rank is 3, which is 25% below median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amcad Biomed stock overvalued right now?
Based on GuruFocus' analysis, Amcad Biomed (ROCO:4188) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$9.54, compared to a current price of NT$14.00 — trading 46.8% above its estimated fair value. The current GF Value Rank is 3, which is 25% below median its 10-year median of 4.00. Amcad Biomed's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Amcad Biomed (ROCO:4188), the current GF Value Rank is 3 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amcad Biomed (ROCO:4188) Overvalued in 2026?

Based on GuruFocus' analysis, Amcad Biomed stock appears to be overvalued. The current stock price of NT$14.00 is trading 46.8% above its estimated GF Value™ of NT$9.54. GuruFocus considers Amcad Biomed to be Significantly Overvalued.

Key valuation signals for ROCO:4188:

  • GF Value Rank: 3 (25% below median its 10-year median of 4.00)
  • GF Value™: NT$9.54 vs. price of NT$14.00 (46.8% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the ROCO:4188 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amcad Biomed Business Description

Address Fuxing N. Road, No. 167, 5th Floor, Zhongshan District, Taipei, TWN, 104
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, AmCAD-UV, AmCAD and AmCAD-UO. Geographically, the company generates revenue from Taiwan, China, Europe, Asia (excluding Taiwan and China), and other countries, out of which the majority of the revenue is generated from Taiwan. The company has two segments: the Medical Diagnostic Software segment, which is responsible for the development and sales of smart medical imaging diagnostic software devices, and the Precision Medical Equipment segment, which is responsible for research, development, manufacturing, and sales of high-end ultrasonic probes. The company generates the majority of its revenue from the Precision Medical Equipment segment.
50GF Score

Get the complete analysis for ROCO:4188

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$14.00
Price
NT$9.54
GF Value